Mono-N-terminal poly(ethylene glycol)-protein conjugates.
about
Site-Specific PEGylation of Therapeutic ProteinsPolymer-drug conjugates: origins, progress to date and future directionsA better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycolBrain delivery of proteins via their fatty acid and block copolymer modificationsN-terminal protein modification using simple aminoacyl transferase substratesToward top-down determination of PEGylation site using MALDI in-source decay MS analysis.An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.Optimized clinical performance of growth hormone with an expanded genetic codeBioactive unnatural somatostatin analogues through bioorthogonal iodo- and ethynyl-disulfide intercalators.Acceleration of diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic rats.Macromolecular therapeuticsAgile delivery of protein therapeutics to CNSGenetic PEGylationPolymer-drug conjugates: recent development in clinical oncologyApplications of orthogonal "click" chemistries in the synthesis of functional soft materials.Protein- and peptide-modified synthetic polymeric biomaterialsNoninvasive Transdermal Vaccination Using Hyaluronan Nanocarriers and Laser Adjuvant.Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents.Synthesis of protein-polymer conjugates.Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand.Collagen-like peptides and peptide-polymer conjugates in the design of assembled materials.Laminin-111 Peptides Conjugated to Fibrin Hydrogels Promote Formation of Lumen Containing Parotid Gland Cell ClustersIn situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics.Polypeptide-polymer bioconjugates.Delivery of therapeutic proteins.PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.Product development issues for PEGylated proteins.Pharmacokinetics and pharmacodynamics of pegfilgrastim.Multifunctional Poly(ethylene glycol)s.Growth factor delivery: how surface interactions modulate release in vitro and in vivo.Antibody-drug conjugates - a perfect synergy.Transglutaminase-mediated macromolecular assembly: production of conjugates for food and pharmaceutical applications.Post-production modification of industrial enzymes.PEGylation and its impact on the design of new protein-based medicines.Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation.Protein-polymer therapeutics: a macromolecular perspective.Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.How PEGylation influences protein conformational stability.Antibacterial activity of polihexanide formulations in a co-culture of HaCaT keratinocytes and Staphylococcus aureus and at different pH levels.Using hydrogen/deuterium exchange mass spectrometry to study conformational changes in granulocyte colony stimulating factor upon PEGylation.
P2860
Q26777819-92F84587-D157-432C-A76C-CC83D8D9CE86Q27002505-EBE7058C-C823-4AD2-B461-A525AF1A9373Q28478454-9B763711-135B-427F-ACF4-EECDF123D515Q30354932-5DED5847-2560-40A2-A88B-151C2CC082E8Q30406776-FCB4290B-F2E7-4023-9892-447A4D657CB8Q33385574-27464169-2270-41B0-B1CD-41DADC64D973Q33412963-DB8894C0-9035-4A70-83E3-0C641289D0FFQ33901953-144E3DE5-40A8-49B2-8FA1-4F2B1CBF5917Q33958534-8BA084D2-1DC7-4622-B0A5-5279D4078794Q34076711-376B2D89-894F-4E77-B3CE-55DD34ECA743Q34079574-9923D356-D3BF-4B8A-943D-195F5BB1C709Q34079647-3C916A53-C2F9-4768-A9A1-05F0F5BFF116Q34474297-44FB13CF-F7FC-42AD-AFD5-702AE33AC1E5Q34656003-B7C63507-CF99-4B3F-9EC1-98B9C094A97EQ35190403-A7FE3A3A-4E16-4D87-B8D2-F2F793CB0F83Q35624524-59B8E7B8-A9B6-4E88-A846-BFF866EA67B2Q36189410-C30BC5EB-630B-48AE-8C24-5868DCBAB4D4Q36214907-AF7BD407-EB9E-4894-87A2-6403781BACD1Q36681987-D83ABB77-CD9C-419F-8D4D-47C5073DF99AQ36777316-8B93C5E9-E554-4333-B172-E350BB4818EDQ37163563-D2B1BB6D-B586-4215-832B-F44E81DAB32CQ37268369-E65AF5B0-74FD-4C73-9484-69293B102E7CQ37318164-9DA2B05A-38AF-4E59-A862-AB3111D8C3A6Q37659998-71199E0C-B7DA-48E8-A54E-771B769D819DQ37668486-36C63382-F931-410D-9789-9CAAC7BC6E42Q37708777-E95FB4AE-DBA7-4425-8A84-C6BFB1A7E71EQ37790702-1369D55E-59E1-4DB3-9D17-13AD6AC933E6Q37860299-1E50247C-05D6-41EA-BFA8-E0D05A81AB2EQ37900556-12AFB6E4-8110-469F-BA6C-03A4CC120C65Q37995448-C88C7B2F-A282-4FD0-A96C-CA7310F57080Q38014923-009F13A9-FF76-4E07-9FED-A4A5E2D1741AQ38122094-A8BEFA68-7D98-4A39-B14E-41A96AF9B6A7Q38218063-2CC23073-81D2-4DF4-871A-57A976D0C6A4Q38269324-88726207-7287-46BE-91FA-1A691FD04FFEQ38497871-430EDA14-36CD-46D2-8500-1D6709216906Q38555997-20948CB1-7B61-462E-B0DB-1BA73A52D6D5Q38696361-DF3ACE2A-2450-4BAE-9319-9A9B56682A63Q38942496-FA9BEF50-395F-468D-ACC6-26EC4188BBC9Q40267001-DE63596B-E0E8-4EB0-8BAA-8A99AB9F570CQ41837261-62C05CCC-6B88-4F12-8D83-B91A8C346B84
P2860
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Mono-N-terminal poly
@nl
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
@ast
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
@en
type
label
Mono-N-terminal poly
@nl
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
@ast
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
@en
prefLabel
Mono-N-terminal poly
@nl
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
@ast
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
@en
P2093
P1476
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
@en
P2093
Colin Gegg
David Ladd
Graham Molineux
Michael Treuheit
Olaf Kinstler
P304
P356
10.1016/S0169-409X(02)00023-6
P407
P577
2002-06-01T00:00:00Z